TRIB2 and central nervous system cancer: Moreover, co‐overexpression of TRIB2 and MAP3K1 (TRIB2High/MAP3K1High) tended to indicate shorter overall survival than other expression combinations in patients with glioma (Figure 7E and Table 4).